(403) 770-2469 info@marvelbiotechnology.com
Marvel Biosciences
  • About Us
  • Technology
    • MB-204
    • Non-Hallucinogenic Neuroplasticity Program
  • News
  • Investors
  • Contact Us
Select Page

Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment

Apr 30, 2025 | News

Calgary, Alberta – April 30, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to share part of the second final data set from its preclinical Rett...

Marvel Biosciences to Give Oral Presentation at the Annual IRSF Rett Syndrome Scientific Meeting

Apr 16, 2025 | News

Calgary, Alberta – April 16, 2025 – Marvel Biosciences Corp. (TSXV: MRVL, OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together “Marvel”), are pleased to announce their acceptance to give an oral presentation at the International Rett...
  • Twitter
Copyright 2022 Marvel Biosciences Corp. All rights reserved.